Sprout Pharmaceuticals CEO Cindy Whitehead Resigns – ValueWalk Premium
Sprout Pharmaceuticals

Sprout Pharmaceuticals CEO Cindy Whitehead Resigns

Cindy Whitehead, the CEO of Sprout Pharmaceuticals who oversaw the first prescription drug to enhance women’s sexual drive, is quitting just two months after the company was bought by Valeant. According to a statement from Valeant, she will, however, continue to consult with Valeant and Sprout executives after her departure.

Sprout Pharmaceuticals - Whitehead successfully shepherded Addyi’s launch
Citing concerns about side effects and limited effectiveness, the Food and Drug Administration rejected in 2010 and in 2013 Sprout’s Addyi, often referred to as the “little pink pill . . .

SORRY!

This content is exclusively for paying members.

If you are subscribed and having an account error please clear cache and cookies if that does not work email [email protected] or click Chat.


X
Saved Articles
X
TextTExtLInkTextTExtLInk

The top investors are reading ValuewalkPremium.

Click here to learn why

0